What to do during Bacillus Calmette-Guerin shortage? Valid strategies based on evidence
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F18%3A10387170" target="_blank" >RIV/00216208:11130/18:10387170 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00064203:_____/18:10387170
Výsledek na webu
<a href="https://doi.org/10.1097/MOU.0000000000000544" target="_blank" >https://doi.org/10.1097/MOU.0000000000000544</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1097/MOU.0000000000000544" target="_blank" >10.1097/MOU.0000000000000544</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
What to do during Bacillus Calmette-Guerin shortage? Valid strategies based on evidence
Popis výsledku v původním jazyce
Purpose of review Over the last decade, the world has experienced health-threatening supply shortages of Bacillus Calmette-Guerin (BCG) immunotherapy for nonmuscle-invasive bladder cancer (NMIBC). We summarize the current literature to assist in treatment decisions in light of suboptimal supply. Recent findings Currently available data do not support a superiority of one BCG strain over the other. Intravesical chemotherapy seems to provide similar results in term of disease progression but not recurrence in intermediate-risk patients. One trial has shown that a 3-year maintenance course of BCG in high-risk NMIBC has no advantage in term of progression or overall survival in comparison with 1-year maintenance. Synergo radiofrequency-induced hyperthermia is a reliable alternative in intermediate or high-risk NMIBC with at least similar recurrence rates compared with BCG. Summary Patients with intermediate-risk NMIBC can be offered multiple instillations of intravesical chemotherapy for up to 12 months. In high-risk patients and in case of BCG shortage, BCG instillations can be terminated when the patient has completed 1 year of maintenance. Mitomycin C is an alternative in lowest risk high-risk (G3Ta) NMIBC, whereas patients with pT1/carcinoma in situ can be offered Synergo with mitomycin C when radical cystectomy is not feasible. Immediate radical cystectomy should always be considered in highest risk NMIBC after weighing up benefit to risk.
Název v anglickém jazyce
What to do during Bacillus Calmette-Guerin shortage? Valid strategies based on evidence
Popis výsledku anglicky
Purpose of review Over the last decade, the world has experienced health-threatening supply shortages of Bacillus Calmette-Guerin (BCG) immunotherapy for nonmuscle-invasive bladder cancer (NMIBC). We summarize the current literature to assist in treatment decisions in light of suboptimal supply. Recent findings Currently available data do not support a superiority of one BCG strain over the other. Intravesical chemotherapy seems to provide similar results in term of disease progression but not recurrence in intermediate-risk patients. One trial has shown that a 3-year maintenance course of BCG in high-risk NMIBC has no advantage in term of progression or overall survival in comparison with 1-year maintenance. Synergo radiofrequency-induced hyperthermia is a reliable alternative in intermediate or high-risk NMIBC with at least similar recurrence rates compared with BCG. Summary Patients with intermediate-risk NMIBC can be offered multiple instillations of intravesical chemotherapy for up to 12 months. In high-risk patients and in case of BCG shortage, BCG instillations can be terminated when the patient has completed 1 year of maintenance. Mitomycin C is an alternative in lowest risk high-risk (G3Ta) NMIBC, whereas patients with pT1/carcinoma in situ can be offered Synergo with mitomycin C when radical cystectomy is not feasible. Immediate radical cystectomy should always be considered in highest risk NMIBC after weighing up benefit to risk.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30217 - Urology and nephrology
Návaznosti výsledku
Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2018
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Current Opinion in Urology
ISSN
0963-0643
e-ISSN
—
Svazek periodika
28
Číslo periodika v rámci svazku
6
Stát vydavatele periodika
GB - Spojené království Velké Británie a Severního Irska
Počet stran výsledku
7
Strana od-do
570-576
Kód UT WoS článku
000452678200015
EID výsledku v databázi Scopus
2-s2.0-85064210938